Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
about
Expanding the Use of Organs from Hepatitis C-Viremic Donors: The Evidence Continues to Build.Cost-effectiveness analysis of elbasvir-grazoprevir regimen for treating hepatitis C virus genotype 1 infection in stage 4-5 chronic kidney disease patients in France.A Guide to the Economics of Hepatitis C Virus Cure in 2017
P2860
Cost-effectiveness of elbasvir/grazoprevir use in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and chronic kidney disease in the United States.
description
2016 nî lūn-bûn
@nan
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
2016年论文
@zh
2016年论文
@zh-cn
name
Cost-effectiveness of elbasvir ...... disease in the United States.
@en
Cost-effectiveness of elbasvir ...... disease in the United States.
@nl
type
label
Cost-effectiveness of elbasvir ...... disease in the United States.
@en
Cost-effectiveness of elbasvir ...... disease in the United States.
@nl
prefLabel
Cost-effectiveness of elbasvir ...... disease in the United States.
@en
Cost-effectiveness of elbasvir ...... disease in the United States.
@nl
P2093
P2860
P356
P1476
Cost-effectiveness of elbasvir ...... disease in the United States.
@en
P2093
P2860
P304
P356
10.1111/JVH.12639
P577
2016-12-13T00:00:00Z